Attached files
file | filename |
---|---|
EX-10.14 - EX-10.14 - UroGen Pharma Ltd. | urgn-ex1014_260.htm |
EX-10.15 - EX-10.15 - UroGen Pharma Ltd. | urgn-ex1015_414.htm |
EX-21.1 - EX-21.1 - UroGen Pharma Ltd. | urgn-ex211_411.htm |
10-K - 10-K - UroGen Pharma Ltd. | urgn-10k_20191231.htm |
EX-31.2 - EX-31.2 - UroGen Pharma Ltd. | urgn-ex312_12.htm |
EX-31.1 - EX-31.1 - UroGen Pharma Ltd. | urgn-ex311_7.htm |
EX-4.2 - EX-4.2 - UroGen Pharma Ltd. | urgn-ex42_412.htm |
EX-32.1 - EX-32.1 - UroGen Pharma Ltd. | urgn-ex321_15.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-235642) and S-8 (Nos. 333-232034, 333-227812, 333-222955, 333-221212 and 333-218992) of UroGen Pharma Ltd. of our report dated March 2, 2020 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
Tel-Aviv, Israel |
/s/Kesselman & Kesselman |
March 2, 2020 |
Certified Public Accountants (Isr.) |
|
A member firm of PricewaterhouseCoopers International Limited |
Kesselman & Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 6812508, Israel, |
P.O Box 50005 Tel-Aviv 6150001 Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il |